CHI3L1 and myeloid sarcoma: In contrary to CHI3L2, CHI3L1 was found to be meaningfully enhanced in the CSF of patients with progressive stage of MS in comparison to RRMS patients, and elevated CSF CHI3L1 levels were identified as an independent predictor of a worsening disability in patients with MS (Gil-Perotin et al., 2019).